Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Correlation of cognitive impairment and thalamic atrophy in MS: For men only?
Animal models of multiple sclerosis: the good, the bad and the bottom line.
Riluzole.
Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes.
Role of the innate and adaptive immune responses in the course of multiple sclerosis.
Excitotoxic mechanisms of ischemic injury in myelinated white matter.
The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.
Glycans of myelin proteins.
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
Oral laquinimod for multiple sclerosis.
Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
A comparison of 12 weeks of pilates and aquatic training on the dynamic balance of women with mulitple sclerosis.
Acute transverse myelitis: an unusual complication of typhoid fever.
AB Science announces successful non futility test for masitinib in progressive forms of multiple sclerosis
Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort.
NMO spectrum presenting as partial myelitis.
The effect of mouse strain on herpes simplex virus type 1 (HSV-1) infection of the central nervous system (CNS).
The Development and Maintenance of Paclitaxel-Induced Neuropathic Pain Requires Activation of the Sphingosine 1-Phosphate Receptor Subtype 1.
Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response.
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
Early phenotypic asymmetry of sister oligodendrocyte progenitor cells after mitosis and its modulation by aging and extrinsic factors.
Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.
The invisible gorilla strikes again: sustained inattentional blindness in expert observers.

Pages